Monoclonal Antibodies Against Carp Beta-Enolase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing fish allergy rely on natural allergen extracts that are of poor quality due to undefined non-allergenic materials, contaminants, and low allergen concentrations, limiting their safety and efficacy in diagnostics and treatment.
Innovation Solution
Development of hybridoma cell lines producing monoclonal antibodies specific to common carp β-enolase, which recognize the enzyme's amino acid sequence and can detect β-enolase in both commercial and natural fish extracts, enabling more detailed characterization and standardization of allergen extracts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural allergen extracts are used for fish allergy diagnosis, then the diagnostic process can be performed, but the quality is poor due to undefined non-allergenic materials, contaminants, and low allergen concentrations
Solution Approach 1:
The patent extracts and isolates specific allergenic proteins (β-enolase and aldolase) from complex fish muscle tissue extracts. By separating these specific allergens from the mixture of undefined non-allergenic materials and contaminants, the invention creates purified allergen preparations that maintain immunological relevance while eliminating quality issues associated with natural extracts
Solution Approach 2:
The patent applies local quality by creating standardized allergen preparations with defined characteristics. Instead of using heterogeneous natural extracts, the invention produces allergen preparations with consistent protein composition, known concentrations, and controlled purity, allowing for reliable diagnostic results while improving manufacturing precision
2Quantity of substance
If natural allergen extracts are used, then diagnostic testing can be conducted, but the allergen concentrations are low limiting efficacy
Solution Approach 1:
The patent changes the concentration parameter of allergens by producing purified preparations with defined and optimized allergen concentrations. This allows for standardized dosing in diagnostic testing and potential immunotherapy, improving efficacy while maintaining reliability through consistent quality control
3Adaptability or versatility
If natural allergen extracts are used, then fish allergy diagnosis can be performed, but the extracts contain undefined non-allergenic materials and contaminants
Solution Approach 1:
The patent extracts specific allergenic proteins (β-enolase and aldolase) from complex fish muscle tissue extracts. By separating these specific allergens from the mixture of undefined non-allergenic materials and contaminants, the invention creates purified allergen preparations that maintain immunological relevance while eliminating quality issues associated with natural extracts
Solution Approach 2:
The patent uses recombinant DNA technology as an intermediary approach, expressing fish allergen proteins in E. coli bacteria. This intermediary system allows for the production of pure allergen proteins without co-extraction of contaminants, while maintaining the immunological properties needed for diagnostic capability
Data Source
Figure 1~3
Figure 4~6
Figure 7
AI summary
The invention belongs to the field of protein biotechnology. New monoclonal antibodies against carp β-enolase and hybridoma cells producing them are described herein. Monoclonal antibodies can be used to detect carp and other fish proteins in foods, and to identify commercial carp extracts.